The Danish Medicines Agency begins ad hoc reassessment of reimbursement status of medicines in ATC groups C09C, C09D and C09X
On 8 March 2010, a number of pharmaceutical companies put generic copies of the angiotensin II antagonist losartan on the market at prices comparable to those of the cheapest ACE inhibitors. See notification about losartan's price drop prepared by the Institute for Rational Pharmacotherapy in the factbox to the right (in Danish only).
Against this background, the Danish Medicines Agency has decided to begin an ad hoc reassessment of reimbursement status of medicines in ATC groups C09C, C09D and C09X, which today carry general conditional reimbursement. The Danish Medicines Agency has requested the Reimbursement Committee to consider the future reimbursement status of these medicines, and the Committee will discuss the question at its meeting on 23 March 2010. Should the Reimbursement Committee recommend changes to the reimbursement status of these medicines to the disadvantage of companies marketing products in the concerned ATC groups, the Committee's recommendation will be submitted for consultation to the companies.
The Danish Medicines Agency closed the reassessment of these medicines with its decision of 16 January 2009 as part of the regular reassessment of reimbursement status of medicines. See link in the factbox to the right.
For further information, please contact the Reimbursement Department, email@example.com.
Danish Medicines Agency, 12 March 2010